{"database":"GEO","file_versions":[{"headers":{"Content-Type":["application/json"]},"body":{"files":{"Other":["ftp://ftp.ncbi.nlm.nih.gov/geo/series/GSE240nnn/GSE240763/"]},"type":"primary"},"statusCode":"OK","statusCodeValue":200}],"scores":null,"additional":{"omics_type":["Transcriptomics"],"species":["Homo sapiens"],"gds_type":["Expression profiling by high throughput sequencing"],"full_dataset_link":["https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE240763"],"repository":["GEO"],"entry_type":["GSE"],"additional_accession":[]},"is_claimable":false,"name":"First-line Sintilimab with P-GEMOX chemotherapy in advanced Extranodal Natural Killer/T cell lymphoma (SPIRIT): a single-arm, multicenter, phase 2 trial","description":"The addition of anti-PD-1 antibody to pegaspargase, gemcitabine and oxaliplatin (P-GEMOX) showed promising activity as first-line therapy in patients with advanced extranodal natural killer/T cell lymphoma, nasal type (ENKTL) in our previous retrospective study. Here, we assessed the clinical outcomes and multi-omics tumor profiling of sintilimab plus P-GEMOX for patients with previously untreated advanced ENKTL in this phase 2 trial.","dates":{"publication":"2026/07/28"},"accession":"GSE240763","cross_references":{"GSM":["GSM7708834","GSM7708845","GSM7708835","GSM7708846","GSM7708847","GSM7708836","GSM7708837","GSM7708848","GSM7708838","GSM7708849","GSM7708839","GSM7708850","GSM7708840","GSM7708830","GSM7708841","GSM7708831","GSM7708842","GSM7708843","GSM7708832","GSM7708844","GSM7708833"],"GPL":["24676"],"GSE":["240763"],"taxon":["Homo sapiens"]}}